Biotech RadarJobs updated

COMPANY

Ansun BioPharma

HQ: San Diego, CA source · ansunbiopharma.com ↗ · West Coast

Clinical Phase 3

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: Parainfluenza Influenza COVID-19 Lower Respiratory Tract Infection Immunocompromised Influenza Infection SAD-RV Infection and COVID-19 Asthma Bronchiectasis DAS181 DAS181-F02 DAS181-F04

10Trials (company is sponsor)

Timeline

  1. Trial start Phase 2/Phase 3: DAS181 for STOP COVID-19 source ↗
  2. Trial start Phase 2: DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19) source ↗
  3. Trial start III: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study source ↗
  4. Trial start II: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental O source ↗
  5. Trial start Phase 2: An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection source ↗
  6. Trial start 2B: Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza source ↗
  7. Trial start Phase 1: A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis source ↗
  8. Trial start II: Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza source ↗
  9. Trial start Phase 1: DAS181 Single Dose Escalation Study in Healthy Adults source ↗
  10. Trial start Phase 1: Single Dose Escalating Study of DAS181 in Adults source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 10

RecordTitlePhaseStatusStartPrimary completion
NCT03808922Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT StudyIIIRecruitingMay 23, 2019Sep 1, 2028 (estimated)
NCT04354389DAS181 for STOP COVID-19Phase 2/Phase 3WithdrawnJul 25, 2020Sep 30, 2020 (estimated)
NCT04298060DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)Phase 2Unknown status (ClinicalTrials.gov)2020-072021-03 (estimated)
NCT00876161DAS181 Single Dose Escalation Study in Healthy AdultsPhase 1CompletedMay 18, 20092009-12 (actual)
NCT01740063Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza2BCompleted2012-112014-01 (actual)
NCT01113034A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or BronchiectasisPhase 1Completed2010-07Aug 22, 2011 (actual)
NCT01644877A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental OxygenIICompleted2014-03Dec 15, 2016 (actual)
NCT01924793An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) InfectionPhase 2Completed2013-082017-05 (actual)
NCT01037205Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed InfluenzaIICompleted2009-122011-09 (actual)
NCT00527865Single Dose Escalating Study of DAS181 in AdultsPhase 1Completed2007-102008-12 (actual)
Feedback